O v ver the past decade, there has been a dramatic increase in the prevalence of infections caused by penicillin-resistant strains of Streptococcus pneumoniae." 2 Although the proportion of penicillin-nonsusceptible isolates varies by geographic region, it is clear that these strains now account for 20-40% of pneumococcal isolates in the United States. A recent 3year multicenter surveillance study involving eight US childrens' hospitals revealed that 21 % of all isolates of S. pneumoniae causing systemic infection were nonsusceptible to penicillin.3 Although previous antibiotic exposure, day care attendance, age less than 3 years, and previous hospitalization have been implicated as risk factors for nonsusceptible systemic pneumococcal infections, these infections can also occur without identifiable risk factors.4
Penicillin resistance appears to be mediated by alterations in the penicillin-binding proteins, which prevent the antimicrobial agent from gaining access into the organism. Acquisition of gene defects that code for altered proteins may be acquired from other resistant organisms.5 Clones of resistant pneumococci, along with other organisms, have spread between geographic locations, and have been tracked epidemiologically. 6 In addition to increasing prevalence of nonsusceptible pneumococcal isolates, the minimum inhibitory concentrations (MICs) of these organisms appear to be on the rise.7 Because the penicillin-binding proteins are responsible for the activity of other beta lactam agents, alterations in these proteins are associated with resistance to other beta lactam agents, such as cephalosporins. In addition, these strains, through other mechanisms, are resistant to many other classes of antimicrobial agents, such as the macrolides.
As a result of the increasing prevalence of nonsusceptible pneumococcal strains, recommendations for the treatment of such infections have evolved.8 In the treatment of meningitis caused by nonsusceptible strains of S. pneumoniae, treatment failures with penicillin and cephalosporin regimens have been clearly documented.9-11 Thus, vancomycin, along with cefotaxime or ceftriaxone, has become the standard empiric regimen for the child with bacterial meningitis, pending culture and susceptibility data. The most ideal therapy for nonmeningeal invasive pneumococcal infections is much less defined than it is for meningitis. Despite increasing resistance, reports of failures with standard antimicrobial regimens for nonmeningeal infections have been extremely rare. This is most likely due to the high serum concentrations attainable with the beta lactam agents, which exceed the minimum inhibitory concentrations for the nonsusceptible strains of S. pneumoniae. To date, there has not been a difference in mortality rates in children or adults infected with penicillin-susceptible, as opposed to penicillin-nonsusceptible strains, of S. pneumoniae. 2, 12 Sabella, Goldfarb In this issue of Clinical Pediatrics, a patient with nephrotic syndrome who experienced bacteremia and cellulitis caused by a penicillinnonsusceptible strain responded well to standard doses of beta lactam antibiotics.
The decision as to what antimicrobial regimen to initiate when S. pneumoniae is a potential pathogen should depend on the clinical disposition of the patient. Immunocompetent patients who are not critically ill but are suspected of having bacteremia or other nonmeningeal infections can be treated with standard beta lactam agents, such as ceftriaxone or cefotaxime. Subsequent therapy can be determined by the clinical response. For critically ill and immunocompromised children, many experts recommend empirically initiating therapy with vancomycin in addition to a beta lactam agent, pending culture and susceptibility results.
The impact of penicillin-nonsusceptible pneumococci goes beyond invasive infections. Because S. pneumoniae remains the most common etiologic agent of otitis media and sinusitis, treatment failures with standard oral antimicrobial agents are becoming more common. Standard doses of amoxicillin and oral cephalosporins may well be inadequate to treat otitis media caused by a nonsusceptible strain of S. pneumoniae. In these situations, therapy with a sulfonamide, cephalosporin, or macrolide is likely to be ineffective, since none of these agents are likely to be as effective as amoxicillin, based on susceptibility data and drug penetration into the middle ear.13 Therapy with high-dose amoxicillin has been advocated to treat such resistant infections.14 There may be times when parenteral therapy for otitis media and sinusitis may be indicated because of the inability of oral agents to achieve adequate levels to kill drug-resistant organisms at these sites of infection.
It is likely that the problem of penicillin-nonsusceptible pneumococcal infections will continue to increase. It is not likely that new antimicrobial agents will help us deal with this critical problem. Strategies to curb the inappropriate and excessive use of antibiotics need to be undertaken and implemented. Additionally, the conjugate pieumococcal vaccines are on the horizon and will likely play an important role in curtailing the epidemic of penicillin-resistant pneumococcal infections.
